微血管乳房重建与激素治疗患者的血栓栓塞事件:三级转诊中心实践审计
该研究回顾2014至2019年240例患者共275个游离皮瓣乳房重建,按术前是否使用激素治疗分组,比较血栓栓塞事件。结果显示激素治疗组与未使用组在微血管血栓、皮瓣并发症及系统性静脉血栓栓塞事件上均无显著差异,不支持术前常规停药2周的做法。
要点
- 激素治疗未显著增加微血管乳房重建患者的血栓栓塞风险。
- 术前停用激素治疗2周的做法未显示对血栓事件或皮瓣存活有益。
- 需大规模试验确立激素治疗围手术期管理的明确方案。
核心结论
- 激素治疗未显著增加微血管乳房重建患者的血栓栓塞事件风险。
- 术前停用激素治疗2周的做法未在血栓栓塞事件或皮瓣存活方面显示获益。
研究设计与样本
- 回顾性审计2014至2019年三级转诊中心所有游离皮瓣乳房重建病例。
- 共240例患者、275个游离皮瓣,按手术时激素用药状态分组。
- 36例在术前一个月内接受激素治疗,术前停药时间中位8.5天(范围0-28天)。
主要发现
- 术中微血管血栓发生率激素治疗组2.0%、未使用组0%,p=0.869。
- 术后微血管并发症/皮瓣再探查率激素治疗组6.6%、未使用组0%,p=0.234。
- 系统性静脉血栓栓塞事件发生率激素治疗组8.3%、未使用组6.1%,p=0.893。
- 年龄、BMI、吸烟状态和术前化疗未影响血栓并发症发生率。
临床怎么用
- 激素治疗不应被视为微血管乳房重建的禁忌,术前常规停药2周缺乏证据支持。
- 临床决策应个体化评估血栓栓塞风险,而非仅依据激素治疗状态。
局限性
- 回顾性审计设计,样本量有限,激素治疗组仅36例。
- 停药时间范围宽(0-28天),未标准化。
- 需大规模试验确立 definitive 围手术期管理方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hormonal therapy with tamoxifen and aromatase inhibitors reduces breast cancer recurrence and mortality but represents a risk factor for thromboembolic events. Therefore, most surgeons discontinue hormonal agents before microvascular surgery and for a variable period thereafter. There are no guidelines regarding when therapy should be stopped (preoperatively) or when it should be resumed (post-operatively). We, therefore, audited our hospital practice with the objective of making recommendations for microvascular breast reconstruction patients. PATIENTS AND METHODS: A review was performed of all free flap breast reconstructions between 2014 and 2019. Patients were classified according to hormone medication status at operation. Timings of drug cessation and recommencement were recorded. Thrombotic events, namely flap microvascular thrombosis, deep vein thrombosis, superficial vein thrombosis and pulmonary embolism, were compared. RESULTS: A total of 240 patients had 275 free flaps over five years with 36 receiving hormone therapy within one month prior to surgery, which was discontinued 8.5 days (range: 0-28 days) before surgery. Intraoperative microvascular thromboses (HT 2.0%, NHT 0%, and p = 0.869) and post-operative microvascular complications/flap re-explorations (HT 6.6%, NHT 0%, and p = 0.234) were comparable between the two groups. Systemic venous thromboembolic events were also similar (HT 8.3%, NHT 6.1%, and p = 0.893). Age, BMI, smoking status and preoperative chemotherapy did not influence the incidence of thrombotic complications. CONCLUSION: Hormone therapy did not significantly increase the risk of thromboembolic events. Despite the widespread practice of withholding it for 2 weeks prior to reconstructive surgery, this study does not support such practice being beneficial in terms of thromboembolic events and flap viability. Large-scale trials are needed to establish definitive protocols.
引用
- Samaras S, Ashfield S, Ali SF, et al. Microvascular breast reconstruction and thromboembolic events in patients on hormone therapy: Audit of practice from a tertiary referral centre. J Plast Reconstr Aesthet Surg. 2020. PMID: 33221183. doi:10.1016/j.bjps.2020.10.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。